Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan

Pfizer

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT00888576

0881A1-4445

Details and patient eligibility

About

The purpose of this study is to develop a registry with safety and efficacy data on the use of etanercept in clinical practice in Taiwan.

Enrollment: 441 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Main Inclusion Criteria: 1) Male or female patients aged > 20 years; 2) Patients who have already been selected and approved under the Taiwan National Health Insurance Program to receive 24 weeks of etanercept for rheumatoid arthritis. Main

Exclusion criteria

Exclusion Criteria: None

Trial design

441 participants in 1 patient group

1

Description:

Non-intervention